Biotech Acquisition Company announced the pricing of its $200 million IPO this evening and its shares are expected to begin trading on the Nasdaq under the symbol “BIOTU” Tuesday, January 26.
The new company intends to focus their search on target businesses in the healthcare sector, with a particular focus on life sciences/biotechnology, healthcare information technology, medical technology and technology-enabled healthcare services. Biotech Acquisition Company is led by Chief Executive Officer and Chairman Dr. Michael Shleifer, COO Ivan Jarry, Chief Investment Officer and Director Albert F. Hummel, and CFO and Treasurer Thomas Fratacci.
Total SPAC deal count for 2021 year-to-date is now 69 with $19.56 billion in gross proceeds raised. This offering is expected to close on Thursday, January 28.
Cantor Fitzgerald & Co. is serving as book-running manager for the offering. Ellenoff Grossman & Schole LLP is serving as Issuer’s Counsel with Reed Smith LLP serving as Underwriter’s Counsel. Marcum LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
Source: https://spacinsider.com/2021/01/25/biotech-acquisition-company-prices-200m-ipo/
